Drugs / IBOCTADEKIN
IBOCTADEKIN
English name Interleukin-18
also known as
SB-485232 · Iboctadekina · Iboctadekine · Ifn-gamma-inducing factor · Il-1 gamma · IL-18 · Interferon gamma-inducing factor · Interleukin-1 gamma · +1 more
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02277392 | Sep 2014 → Jun 2015 | uterine adnexa cancer | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT01768338 | Feb 2013 → Mar 2016 | non-Hodgkin lymphoma | Michael John Robertson | Completed | No outcome recorded |
| Phase 1 | NCT00659178 | Jun 2008 → Feb 2011 | ovarian epithelial tumor | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00500058 | Jul 2007 → Mar 2010 | non-Hodgkin lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00085904 | Apr 2004 → ? | lymphoma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00085878 | Jan 2003 → ? | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00107718 | Nov 2004 → May 2006 | melanoma | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBOCTADEKIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Iboctadekina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Iboctadekine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Ifn-gamma-inducing factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Il-1 gamma | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | IL-18 | “recombinant human interleukin-18 (SB-485232, IL-18) treatment” NCT02277392 ↗ |
| Known as | Interferon gamma-inducing factor | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Interleukin-1 gamma | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108034 ↗ |
| Known as | Recombinant Human Interleukin-18 | “Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion” NCT00500058 ↗ |
| Known as | SB-485232 | “recombinant human interleukin-18 (SB-485232, IL-18) treatment” NCT02277392 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-18” NCT00500058 ↗ |
| Route | Subcutaneous | “Subjects will receive SB-485232 administered as subcutaneous injections daily for 14 days.” NCT00085878 ↗ |